{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:19:11Z","timestamp":1794572351162,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"All funding in the project was supported by the Presidency of Turkish Health Institutes (TUSEB) with grant number 4293."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1038\/s41417-023-00709-9","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T03:02:21Z","timestamp":1702522941000},"page":"387-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Enhancing CAR-T cells: unleashing lasting impact potential with phytohemagglutinin activation in in vivo leukemia model"],"prefix":"10.1038","volume":"31","author":[{"given":"Berranur","family":"Sert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Gulden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Teymur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasin","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raife Dilek","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur Mert","family":"Unaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elanur","family":"Guzenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza Emir","family":"Erdil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevim","family":"Isik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilknur","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samed","family":"Ozer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahire","family":"Yurdakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2055-8247","authenticated-orcid":false,"given":"Osman","family":"Kamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ercument","family":"Ovali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevzat","family":"Tarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4173-6634","authenticated-orcid":false,"given":"Cihan","family":"Tastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"709_CR1","unstructured":"Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019 global survey. Geneva: World Health Organization; 2020;136."},{"key":"709_CR2","unstructured":"American Cancer Society. Cancer facts & figures 2021\u20132022. The American Cancer Society journal, CA: A Cancer Journal for Clinicians. 2021. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2021.html."},{"key":"709_CR3","unstructured":"JJaneway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. Part V, The Immune System in Health and Disease. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK10775\/."},{"key":"709_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235\u201371. https:\/\/doi.org\/10.1146\/annurev-immunol-031210-101324.","journal-title":"Annu Rev Immunol"},{"key":"709_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nri1148","volume":"3","author":"M Croft","year":"2003","unstructured":"Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol. 2003;3:609\u201320. https:\/\/doi.org\/10.1038\/nri1148.","journal-title":"Nat Rev Immunol"},{"key":"709_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5483\/bmbrep.2012.45.1.005","volume":"45","author":"DS Vinay","year":"2012","unstructured":"Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep. 2012;45:5\u201312. https:\/\/doi.org\/10.5483\/bmbrep.2012.45.1.005.","journal-title":"BMB Rep"},{"key":"709_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017a;5:22 https:\/\/doi.org\/10.1186\/s40364-017-0102-y.","journal-title":"Biomark Res"},{"key":"709_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/gt.2017.10","volume":"24","author":"L Zhang","year":"2017","unstructured":"Zhang L, Yu Z, Muranski P, Palmer DC, Restifo NP, Rosenberg SA, et al. Inhibition of TGF-\u03b2 signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther. 2017b;24:201\u201310. https:\/\/doi.org\/10.1038\/gt.2017.10.","journal-title":"Gene Ther"},{"key":"709_CR9","doi-asserted-by":"publisher","unstructured":"Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy, 2020;22:57\u201369. https:\/\/doi.org\/10.1016\/j.jcyt.2019.12.004.","DOI":"10.1016\/j.jcyt.2019.12.004"},{"key":"709_CR10","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3389\/fonc.2020.01582","volume":"10","author":"JD Patterson","year":"2020","unstructured":"Patterson JD, Henson JC, Breese RO, Bielamowicz KJ, Rodriguez A. CAR T cell therapy for pediatric brain tumors. Front Oncol. 2020;10:1582 https:\/\/doi.org\/10.3389\/fonc.2020.01582.","journal-title":"Front Oncol"},{"key":"709_CR11","doi-asserted-by":"publisher","unstructured":"Blaeschke F, Kaeuferle T, Feucht J, Weber D, Lotfi R, Kaiser A, et al. Defined central memory and stem memory T cell phenotype of CD4 and CD8 CAR T cells for the treatment of CD19+ acute lymphoblastic leukemia in an automated closed system. Blood. 2016;128:4558. https:\/\/doi.org\/10.1182\/blood.V128.22.4558.4558.","DOI":"10.1182\/blood.V128.22.4558.4558"},{"key":"709_CR12","doi-asserted-by":"publisher","unstructured":"Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser AD, et al. Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia. Cancer Immunol Immunother. 2018;67:1053\u201366. https:\/\/doi.org\/10.1007\/s00262-018-2155-7.","DOI":"10.1007\/s00262-018-2155-7"},{"key":"709_CR13","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Cantillo G, Urue\u00f1a C, Camacho BA, Ram\u00edrez-Segura C. CAR-T cell performance: how to improve their persistence? Front Immunol. 2022;13:878209. https:\/\/doi.org\/10.3389\/fimmu.2022.878209.","DOI":"10.3389\/fimmu.2022.878209"},{"key":"709_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3.","journal-title":"Lancet"},{"key":"709_CR15","doi-asserted-by":"publisher","unstructured":"Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014a;20:119\u201322. https:\/\/doi.org\/10.1097\/PPO.0000000000000035.","DOI":"10.1097\/PPO.0000000000000035"},{"key":"709_CR16","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl J Med. 2014b;371:1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N. Engl J Med"},{"key":"709_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013a;3:388\u201398. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0548.","journal-title":"Cancer Discov"},{"key":"709_CR18","doi-asserted-by":"publisher","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2013b;25:267\u201376. https:\/\/doi.org\/10.1016\/j.coi.2009.02.009.","DOI":"10.1016\/j.coi.2009.02.009"},{"key":"709_CR19","doi-asserted-by":"publisher","unstructured":"Duarte RF, Chen FE, Lowdell MW, Potter MN, Lamana ML, Prentice HG, et al. Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy. Gene Ther. 2002;9:1359\u201368. https:\/\/doi.org\/10.1038\/sj.gt.3301807.","DOI":"10.1038\/sj.gt.3301807"},{"key":"709_CR20","doi-asserted-by":"publisher","unstructured":"Gulden G, Sert B, Teymur T, Ay Y, Tiryaki NN, Mishra AK, et al. CAR-T cells with phytohemagglutinin (PHA) provide anti-cancer capacity with better proliferation, rejuvenated effector memory, and reduced exhausted T Cell frequencies. Vaccines. 2023;11:313. https:\/\/doi.org\/10.3390\/vaccines11020313.","DOI":"10.3390\/vaccines11020313"},{"key":"709_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/B978-0-12-418687-3.00018-5","volume":"529","author":"PA Longo","year":"2013","unstructured":"Longo PA, Kavran JM, Kim MS, Leahy DJ. Transient mammalian cell transfection with polyethylenimine (PEI). Methods Enzymol. 2013;529:227\u201340. https:\/\/doi.org\/10.1016\/B978-0-12-418687-3.00018-5.","journal-title":"Methods Enzymol"},{"key":"709_CR22","unstructured":"Morgan LR, Krementz ET, Fan SW, Fan D. Adoptive immunotherapy of advanced renal cell cancer using PHA-stimulated autologous lymphocytes. Anticancer Res. 1993;13:1763\u20137."},{"key":"709_CR23","doi-asserted-by":"publisher","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024\u20138. https:\/\/doi.org\/10.1073\/pnas.86.24.10024.","DOI":"10.1073\/pnas.86.24.10024"},{"key":"709_CR24","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2016-01-695122","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, et al. Phase 1 studies of central memory derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127:2980\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-695122.","journal-title":"Blood"},{"key":"709_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227\u201342. https:\/\/doi.org\/10.1038\/nri3405.","journal-title":"Nat Rev Immunol"},{"key":"709_CR26","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010;107:4275\u201380. https:\/\/doi.org\/10.1073\/pnas.0915174107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"709_CR27","doi-asserted-by":"publisher","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","volume":"181","author":"AL Kinter","year":"2008","unstructured":"Kinter AL, Godbout EJ, McNally JP, Riggin L, Sereti I, Roby G, O\u2019Shea M, Fauci AS. The common \u03b3-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181:6738\u201346. https:\/\/doi.org\/10.4049\/jimmunol.181.10.6738.","journal-title":"J Immunol"},{"key":"709_CR28","doi-asserted-by":"crossref","unstructured":"Movafagh A, Heydary H, Mortazavi-Tabatabaei SA, Azargashb E. The significance application of indigenous phytohemagglutinin (PHA) mitogen on metaphase and cell culture procedure. Iran J Pharm Res. 2011;10:895.","DOI":"10.4238\/2001.November.25.3"},{"key":"709_CR29","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.immuni.2016.04.017","volume":"44","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Vignali DAA. Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity. 2016;44:1034\u201351. https:\/\/doi.org\/10.1016\/j.immuni.2016.04.017.","journal-title":"Immunity"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-023-00709-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-023-00709-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-023-00709-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:04:01Z","timestamp":1710461041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-023-00709-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1038\/s41417-023-00709-9","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CT, BS, GG, TT, and YA are inventors of patent applications (pending) including \u201cAllogeneic CAR-T cells expressing bispecific chimeric antigen receptors (CARs) targeting CD19 along with CD20 or CD22\u201d (PCT\/TR2023\/050541 and 2022\/009703) at Turkish Patent and Trademark Office. No other author has a competing interest except for these authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"In vitro and in vivo studies were approved by the Acibadem University and Acibadem Healthcare Institutions Medical Research Ethics Committee (ATADEK-2019-17\/31). All animal studies have been approved by Ac\u0131badem University Animal Experiments Local Ethics Committee (ACU-HADYEK; 11.13.2019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}